Related Experiment Video

Updated: Apr 20, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.8K

[Research on progress and prospect of kinase S6K1]

Hui Zhang, Junyu Liang, Ji Zhang

    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi
    |December 4, 2014
    PubMed

    Insights

    Obesity, a global health issue, is linked to Kinase S6K1 (S6K1), a key part of the mTOR pathway. Targeting S6K1 offers a promising therapeutic strategy for obesity and related diseases.

    Area of Science:

    • Metabolic disorders
    • Molecular biology
    • Oncology

    Background:

    • Obesity is a major global health concern with significant health implications.
    • Kinase S6K1 (S6K1), a downstream target of the mammalian target of rapamycin (mTOR) pathway, plays a crucial role in metabolic regulation.
    • Dysregulation of S6K1 is implicated in the pathogenesis of obesity, type 2 diabetes, and cancer.

    Purpose of the Study:

    • To review the multifaceted functions of Kinase S6K1 (S6K1).
    • To elucidate the molecular mechanisms regulating S6K1.
    • To explore the role of S6K1 in disease pathogenesis and discuss potential therapeutic strategies involving small molecular inhibitors.

    Main Methods:

    • Literature review of S6K1 functions.
    • Analysis of molecular regulation pathways of S6K1.
    • Examination of S6K1's role in metabolic diseases and cancer.
    • Survey of small molecule inhibitors targeting S6K1.

    Main Results:

    • S6K1 is a critical mediator in pathological responses, including obesity, type 2 diabetes, and cancer.
    • Understanding S6K1's molecular regulation provides insights into disease mechanisms.
    • Small molecular inhibitors targeting S6K1 show therapeutic potential.

    Conclusions:

    • Kinase S6K1 (S6K1) is a significant therapeutic target for metabolic disorders like obesity and type 2 diabetes, as well as cancer.
    • Further research into S6K1 pathways and inhibitors is warranted to develop effective treatments.

    More Related Videos

    Assaying Protein Kinase Activity with Radiolabeled ATP08:05

    Assaying Protein Kinase Activity with Radiolabeled ATP

    Published on: May 26, 2017

    19.6K
    Assaying the Kinase Activity of LRRK2 in vitro06:09

    Assaying the Kinase Activity of LRRK2 in vitro

    Published on: January 18, 2012

    23.1K

    Related Concept Videos

    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.5K
    Protein Kinases and Phosphatases02:54

    Protein Kinases and Phosphatases

    4.7K
    Protein Kinases and Phosphatases02:54

    Protein Kinases and Phosphatases

    Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
    Protein kinases
    Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
    15.8K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.3K
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    9.5K
    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    14.2K